Arrhythmias & electrophysiology
Effects of Implantable Cardioverter-Defibrillator Leads on the Tricuspid Valve and Right Ventricle: A Randomized Trial
Primary result · TRResult — go to the resultOdds ratio 7.2 95% CI 3.3–15.8Authors' conclusion
Six months following TV-ICD insertion, there was a 7-fold increase in the risk of at least 1 grade worsening of TR, with 7% of individuals having TR that was moderate or severe. There was no detectable difference in RV size or function
Study context
- Population
- Adults randomised to transvenous or subcutaneous ICD
- Participants
- 252 vs 251
- Comparison
- Transvenous implantable cardioverter-defibrillator (TV-ICD) vs subcutaneous implantable cardioverter-defibrillator (S-ICD)
- TV-ICDn = 252
- S-ICDn = 251reference
- Primary endpoint
- TR severity
- Follow-up
- 6 months after ICD insertion
Methodological detailscore laboratory echocardiography, Echocardiographic images analysed in a core laboratory
- Core laboratory echocardiography
- Echocardiographic images analysed in a core laboratory
Primary result
TR · 6 months
Odds ratio
7.2
95% CI 3.3–15.8
P < 0.001
By group
TV-ICD
- Any tricuspid regurgitation (TR)
- 42%
- Moderate or severe TR
- 7%
S-ICD
- Any TR
- 19%
- Moderate or severe TR
- 2%
Any tricuspid regurgitation (TR)
TV-ICD42%
S-ICD19%
Moderate or severe TR
TV-ICD7%
S-ICD2%
TV-ICDvs S-ICD
OR 7.2 (95% CI 3.3–15.8); P < 0.001
As reported in the abstract
Further findings
Right ventricular (RV) size and systolic function · 6 months
- No differences between groups
Original publication
Effects of Implantable Cardioverter-Defibrillator Leads on the Tricuspid Valve and Right Ventricle: A Randomized Trial. JACC Clin Electrophysiol. Published 10 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →